@inproceedings{bourliere:hal-01162707,
TITLE = {O112 : HBsAg clearance after addition of 48 weeks of pegifn in HBeAg negative CHB patients on nucleos(T)ide therapy with undetectable hbvdna for at least one year: final results from ANRS-HB06 pegan study: multicenter randomized controlled phase III trial},
AUTHOR = {Bourli{\`e}re, M. and Rabiega, P. and Ganne-Carrie, N. and Serfaty, L. and Marcellin, P. and Pouget, N. and Guyader, D. and Hezode, C. and Picon, Maurice and Causse, X. and Leroy, V. and Bronowicki, J. P. and Riachi, G. and Rosa, I. and Attali, P. and Molina, J. M. and Bacq, Y. and Tran, A. and Grang{\'e},
J. D. and Zoulim, F. and Fontaine, H. and Bertucci, I. and Bouvier-Alias, M. and Carrat, F. and Benhamou, Y},
URL = {https://univ-rennes.hal.science/hal-01162707},
BOOK
TITLE = {The International Liver Congress™ 2015 -- 50th Annual meeting of the European Association for the Study of the Liver},
ADDRESS = {Vienne, Austria},
VOLUME = {62, Supplement 2},
PAGES = {S249},
YEAR = {2015},
MONTH = Apr, DOI = {10.1016/S0168-8278(15)30131-8},
HAL_ID = {hal-01162707},
HAL_VERSION = {v1},
}